



Market Announcement

4 February 2026

Neuren Pharmaceuticals Limited (ASX: NEU) – Trading Halt

Trading in the securities of Neuren Pharmaceuticals Limited ('NEU') will be halted at the request of NEU, pending the release of an announcement by NEU.

Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of:

- the commencement of normal trading on Friday, 6 February 2026; or
- the release of the announcement to the market.

NEU's request for a trading halt is attached below for the information of the market.

Issued by

ASX Compliance

4 February 2026

Yulia Gurdina
Senior Adviser, Listings Compliance
By Email

Dear Yulia,

Neuren Pharmaceuticals Ltd (ASX:NEU) (Neuren/Company) – Request for Trading Halt

The Directors of Neuren Pharmaceuticals Limited (ASX Code: NEU) hereby request an immediate halt in trading of the Company's securities with effect from prior to commencement of trading today, 4 February 2026.

In accordance with Listing Rule 17.1, the Company provides the following information in relation to the request:

- The trading halt is requested pending an announcement by Neuren regarding US Food & Drug Administration feedback on NNZ-2591 in Pitt Hopkins syndrome and Hypoxic-ischemic encephalopathy (HIE);
- Neuren requests that the trading halt remain in place until the earlier of open trade on Friday 6 February 2026 or the release of an announcement by the Company; and
- Neuren is seeking the trading halt to assist in managing its disclosure obligations and to maintain an orderly market in the trading of the Company's shares.

Neuren confirms that it is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market regarding the trading halt.

Yours sincerely,

Lauren Frazer
Company Secretary